Interview with Bill Guo, Chairman and Founder, Venturepharm
Venturepharm is the most diversified company we’ve seen, throughout many verticals, taking a full-service plus…
Address: Venturepharm Tower, N.3 Jinzhuang Siji Qing Haidian District, Beijing,China
Tel: +86 10 8850 0070
Web: http://www.venturepharm.com/
Venturepharm Asia is a global life science leader with a strategic focus on venture capital, merchant banking, CRO, CMO, CSO, compound partnering, and royalty sharing. The group develops an innovative full service plus model to position itself strongly in the life science industry. Currently Venturepharm Asia has more than two thousand employees.
Financial Services
Venturepharm is the most diversified company we’ve seen, throughout many verticals, taking a full-service plus…
The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…